Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer.
Li X, Gera L, Zhang S, Chen Y, Lou L, Wilson LM, Xie ZR, Sautto G, Liu D, Danaher A, Mamouni K, Yang Y, Du Y, Fu H, Kucuk O, Osunkoya AO, Zhou J, Wu D.
Li X, et al. Among authors: danaher a.
Theranostics. 2021 May 8;11(14):6873-6890. doi: 10.7150/thno.49235. eCollection 2021.
Theranostics. 2021.
PMID: 34093859
Free PMC article.